Inhibikase Therapeutics, Inc.
IKT
$2.41
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -46.10% | -39.43% | -75.36% | -143.58% | -125.79% |
| Total Depreciation and Amortization | -52.69% | 47.38% | 129.55% | 154.55% | 89.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.42% | 1.05% | 150.06% | 6,263.35% | 5,377.67% |
| Change in Net Operating Assets | -17.17% | -263.20% | -72.73% | -176.93% | -7.27% |
| Cash from Operations | -114.08% | -84.39% | -45.11% | -48.54% | -20.86% |
| Capital Expenditure | 100.00% | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,064.42% | -688.03% | 105.58% | -10,119.60% | -137.56% |
| Cash from Investing | -2,058.99% | -687.19% | 105.55% | -10,123.35% | -137.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 11.44% | 8.03% | 4.82% | 2,535.08% | 2,665.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -177.85% | -- |
| Cash from Financing | 11.43% | 8.00% | 4.82% | 2,624.40% | 2,776.18% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -162.33% | -133.58% | 74.81% | 367.83% | 6,219.31% |